| Drug ID: | Drug52 |
|---|---|
| Drug Name: | Iron |
| CID: | 23925 |
| DrugBank ID: | DB01592 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | NO |
| Other Approved: | YES |
| Identifier: | NCT01017614, , NCT03441893 |
| Molecular Formula: | Fe |
| Molecular Weight: | 55.84 g/mol |
| Isomeric SMILES: | [Fe] |
| Synonyms: | IRON; 7439-89-6; Iron, elemental; Ferrum; Iron powder; Remko; Armco iron; Ferrovac E; Ancor B; hierro |
| Phase 0: | 4 |
| Phase 1: | 19 |
| Phase 2: | 46 |
| Phase 3: | 81 |
| Phase 4: | 92 |
| Description: | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt472 | 23925 | Iron | 3040 | HBA2 | Homo sapiens (human) | Activator | |
| dt473 | 23925 | Iron | 7037 | TFRC | Homo sapiens (human) | 16564538 | None |
| dt474 | 23925 | Iron | 54583 | EGLN1 | Homo sapiens (human) | 16649251 | None |
| dt475 | 23925 | Iron | 55869 | HDAC8 | Homo sapiens (human) | 16681389 | Cofactor |
| dt476 | 23925 | Iron | 51327 | AHSP | Homo sapiens (human) | 16901899 | None |
| dt477 | 23925 | Iron | 2395 | FXN | Homo sapiens (human) | 16911956 | None |
| dt478 | 23925 | Iron | 2495 | FTH1 | Homo sapiens (human) | 17070541 | None |
| dt479 | 23925 | Iron | 2237 | FEN1 | Homo sapiens (human) | 20622253 | None |
| dt480 | 23925 | Iron | 79661 | NEIL1 | Homo sapiens (human) | 20622253 | None |
| dt481 | 23925 | Iron | 252969 | NEIL2 | Homo sapiens (human) | 20622253 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| NCT01438372 | IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD | PHASE2 | WITHDRAWN | Wayne State University | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Intravenous iron sucrose|DRUG: Oral ferrous… | Details |
| NCT02774057 | Trial of Captafer vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD | PHASE4 | UNKNOWN | American University of Beirut Medical Center | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Captafer|DRUG: Iron Sulfate | Details |
| NCT02760940 | Anemia in Inflammatory Bowel Disease | PHASE4 | UNKNOWN | Federal University of Juiz de Fora | Anemia|Bowel Diseases, Inflammatory | DRUG: oral liposomal iron | Details |
| NCT03376230 | Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease | None | TERMINATED | University Hospital, Lille | Inflammatory Bowel Diseases | OTHER: Collect of blood, urines, and intestinal b… | Details |
| NCT03457571 | Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome | None | COMPLETED | Charite University, Berlin, Germany | Inflammatory Bowel Diseases|Restless Legs Syndrom… | None | Details |
| NCT00810030 | FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR | PHASE3 | COMPLETED | Vifor Pharma | Inflammatory Bowel Disease|Anemia|Iron Deficiency… | DRUG: Ferric carboxymaltose|DRUG: Iron Sucrose | Details |
| NCT06120322 | Machine Learning Approach to Study the Interactions Between Environment and Intestinal Tissue Homeostasis in IBD | None | NOT_YET_RECRUITING | IRCCS San Raffaele | Diabetes Mellitus, Type 1|Ulcerative Colitis | OTHER: Environmental factor monitoring; collectio… | Details |
| NCT05225545 | Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis | PHASE3 | RECRUITING | American University of Beirut Medical Center | Anemia, Iron Deficiency|Ulcerative Colitis | DRUG: Sucrosomial Iron|DRUG: Oral Iron | Details |
| NCT03282903 | The PRognostic Effect of Environmental Factors in Crohn's and Colitis | None | COMPLETED | University of Edinburgh | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | None | Details |
| NCT03247816 | Feraccru Real World Effectiveness Study in Hospital Practice ( FRESH ) | None | COMPLETED | Shield Therapeutics | Anemia, Iron Deficiency|Inflammatory Bowel Diseas… | None | Details |
| NCT01017614 | Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia | PHASE3 | COMPLETED | Pharmacosmos A/S | Inflammatory Bowel Disease | DRUG: Monofer; DRUG: Iron Sulphate | Details |
| NCT05176795 | Host-microbiota-environment Interactions | Not Available | RECRUITING | University Hospital, Clermont-Ferrand | Juvenile Idiopathic Arthritis; Diabetes type1; In… | OTHER: Stool sample | Details |
| ChiCTR2500100314 | Analysis of iron-related indexes and disease association in patients with inflammatory bowel disease | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University | Inflammatory bowel disease | IBD patients:None; | Details |
| DRKS00034606 | CEDATA GPGE Patient Registry - Registry for chronic inflammatory bowel diseases in children and adolescents - CEDATA | Not Available | Recruiting | Gesellschaft f Piatrische Gastroenterologie und Ernrung e. V. | Inflammatory Bowel Disease K50-K52;Noninfective … | Group 1: Health Care Data is entered into an onli… | Details |
| NCT02517151 | Iron Supplementation in Inflammatory Bowel Disease (IBD) Patients With Chronic Fatigue | PHASE2 | UNKNOWN | Istituto Clinico Humanitas | Chronic Fatigue|Inflammatory Bowel Disease | DRUG: Ferric carboxymaltose|DRUG: Placebo | Details |
| ACTRN12624000016538 | Longitudinal study of diet, lifestyle and biomarker predictors of pouchitis | Not Available | Not Recruiting | Monash University | Inflammatory bowel disease;familial adenomatous p… | We will be following individuals with an ileoanal… | Details |
| ChiCTR2200066959 | Study on the effect of iron supplementation on the efficacy of anti-TNF-a monoclonal antibody in patients with IBD | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Inflammatory bowel disease | Intervention group :iron isomaltoside;Control gro… | Details |
| ChiCTR2200066056 | A comparative study of iron isomaltoside versus traditional iron supplements in patients with inflammatory bowel diseases and iron deficiency anemia | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Inflammatory bowel disease | Intervention group:iron isomaltoside;Control grou… | Details |
| EUCTR2022-000894-16-NL | Predicting Response to Iron Supplementation in Patients with active Inflammatory Bowel Disease_ - PRIme | PHASE4 | Not Recruiting | Leiden University Medical Center | Inflammatory Bowel Disease MedDRA version: 20.0_… | Trade Name: Feraccru Pharmaceutical Form: Capsule… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Environmental risk factors in inflammatory bowel disease: a population-based ca…
PMID: 25217388
Year: 2015
Relationship Type:
Association
Score: 6.3
PURPOSE: X-linked inhibitor of apoptosis (XIAP) deficiency caused by mutations in BIRC4 was originally described in male patients with X-linked lym…
Iron deficiency: the hidden miscreant in inflammatory bowel disease
PMID: 25213175
Year: 2014
Relationship Type:
Treatment
Score: 6.3
Spondyloarthritis (SpA) is a chronic inflammatory disease with either predominantly axial symptoms of the spine and sacroiliac joints (axial SpA, i…
Environmental triggers for IBD
PMID: 25048010
Year: 2014
Relationship Type:
Association
Score: 6.3
BACKGROUND AND OBJECTIVES: Faecal calprotectin is a valuable noninvasive marker for inflammatory bowel disease (IBD). The aim of our study was to de…
Special issue on the Challenges in Environmental Science and Engineering, CESE-…
PMID: 24906212
Year: 2014
Relationship Type:
Association
Score: 6.3
Comment on Gut. 2014 Jan;63(1):72-9.
Intravenous iron in inflammatory bowel disease
PMID: 24890797
Year: 2014
Relationship Type:
Association
Score: 6.3
Iron deficiency in Crohn's disease: iron supplementation or disease control?
PMID: 24726636
Year: 2014
Relationship Type:
Association
Score: 6.3
Current practice in the diagnosis and management of IBD-associated anaemia and …
PMID: 24721157
Year: 2014
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Antibiotics are often given for inflammatory bowel disease (IBD) exacerbations, but their use among pediatric inpatients has not been as…
A novel pathway by which the environmental toxin 4-Nonylphenol may promote an i…
PMID: 24717721
Year: 2014
Relationship Type:
Mechanism
Score: 6.3
Comment in Nature. 2014 Feb 27;506(7489):441-2. Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):202. Cell Cycle. 2014;13(18):2803-4. Crohn…
Epidemiological studies of migration and environmental risk factors in the infl…
PMID: 24574798
Year: 2014
Relationship Type:
Association
Score: 6.3
The diagnosis and management of inflammatory bowel disease (IBD) in Asia can be challenging as certain infections can mimic IBD and lead to a misdia…
Environment and risk of Crohn's disease: comments on "the increasing weight of …
PMID: 24562176
Year: 2014
Relationship Type:
Clinical Trial
Score: 6.3
Iron treatment and inflammatory bowel disease: what happens in real practice?
PMID: 24486177
Year: 2014
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Vitamin D may mediate immunomodulatory effects in patients with inflammatory bowel disease (IBD). The relationships between disease acti…
Environmental gradients predict the genetic population structure of a coral ree…
PMID: 24320929
Year: 2014
Relationship Type:
Treatment
Score: 6.3
CONTEXT: High concentration of 5-amino salicylic acid (5-ASA) in the distal ileum and colon is necessary for the treatment of inflammatory bowel dis…
Environmental factors in a population-based inception cohort of inflammatory bo…
PMID: 24315795
Year: 2014
Relationship Type:
Treatment
Score: 6.3
Ulcerative colitis and Crohn's disease are the major forms of inflammatory bowel disease. Cytokines of the tumor necrosis factor (TNF) family play a…
Gene-gene and gene-environment interactions in ulcerative colitis
PMID: 24241240
Year: 2014
Relationship Type:
Association
Score: 6.3
OBJECTIVE: To examine whether hospital type (children's hospital or generalist hospital) and surgeon specialty are associated with variations in sur…
Anti-mouse CD52 monoclonal antibody ameliorates iron-deficient anaemia in IL-10…
PMID: 24160470
Year: 2014
Relationship Type:
Treatment
Score: 6.3
Inflammatory bowel disease (IBD) is a chronic relapsing immune-mediated inflammatory disorder that affects millions of people around the world. Lept…
Expression of iron-related proteins in the duodenum is up-regulated in patients…
PMID: 24160450
Year: 2014
Relationship Type:
Mechanism
Score: 6.3
Mechanisms responsible for derangements in Fe homeostasis in chronic inflammatory conditions are not entirely clear. The aim of the present study was…
Cytokine-dependent regulation of dendritic cell differentiation in the splenic …
PMID: 24136200
Year: 2014
Relationship Type:
Association
Score: 6.3
The DC-derived chemokine CCL17, a ligand of CCR4, has been shown to promote various inflammatory diseases such as atopic dermatitis, atherosclerosis,…
Genetic isolation by environment or distance: which pattern of gene flow is mos…
PMID: 24111567
Year: 2014
Relationship Type:
Association
Score: 6.3
In classical quantitative genetics, the correlation between the phenotypes of individuals with unknown genotypes and a known pedigree relationship i…
Environmental versus geographical determinants of genetic structure in two suba…
PMID: 24102203
Year: 2014
Relationship Type:
Treatment
Score: 6.3
Erratum in PLoS One. 2013;8(7). doi:10.1371/annotation/b08ddcc9-dfdb-4fc1-b2ac-5a4af3051a91. INTRODUCTION: Members of the human intestinal micr…
Gene-environment interactions in inflammatory bowel disease: microbiota and gen…
PMID: 28839661
Year: 2012
Relationship Type:
Treatment
Score: 6.1
INTRODUCTION: Recent studies have indicated that patients are showing increased interest in playing a larger role in making decisions regarding thei…